Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Neoadjuvant Chemoradiation Plus Veliparib or Pembrolizumab Fails to Improve NAR Score in Locally Advanced Rectal Cancer

January 21st 2023

Both veliparib plus total neoadjuvant therapy and pembrolizumab plus total neoadjuvant therapy failed to improve short-term outcomes in unselected patients with locally advanced rectal cancer.

Bevacizumab Plus TAS-102 Increases Survival and DCR in mCRC

January 21st 2023

Third-line bevacizumab plus trifluridine/tipiracil demonstrated a survival and disease control benefit vs trifluridine/tipiracil alone in patients with refractory metastatic colorectal cancer and all clinically relevant subgroups.

Newer Therapies Demonstrate Real-world Benefit Vs Sorafenib in First-line HCC

January 21st 2023

Newer frontline therapies demonstrated a real-world improvement in survival and responses compared with sorafenib in patients with hepatocellular carcinoma.

CD40-Directed SEA-CD40 Combo Denotes Antitumor Activity in Pancreatic Ductal Adenocarcinoma

January 21st 2023

The combination of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab demonstrated early evidence of efficacy in patients with metastatic pancreatic ductal adenocarcinoma, according to updated results from the phase 1 SGNS40-001 study.

Modest Clinical Benefit Is Observed With or Without Bevacizumab Added to Atezolizumab/Chemotherapy in BTC Signal Seeking Study

January 21st 2023

Treatment with or without bevacizumab added to atezolizumab plus cisplatin/gemcitabine demonstrated a modest clinical benefit for patients with advanced biliary tract cancer.

Tislelizumab Provides QOL Benefit Over Sorafenib in Unresectable HCC

January 21st 2023

Tislelizumab monotherapy resulted in favorable health-related quality of life outcomes compared with sorafenib as frontline treatment for patients with unresectable hepatocellular carcinoma.

Sorafenib Plus SBRT Improves Survival in Locally Advanced HCC

January 21st 2023

The addition of stereotactic body radiation therapy to sorafenib led to an improvement in overall survival, progression-free survival, and time to disease progression compared with sorafenib alone in patients with locally advanced, hepatocellular carcinoma.

Nab-Paclitaxel Plus Gemcitabine/Cisplatin Does Not Significantly Improve OS in Newly Diagnosed, Advanced Biliary Tract Cancers

January 21st 2023

The addition of nab-paclitaxel to gemcitabine and cisplatin did not result in a statistically significant improvement in overall survival over gemcitabine/cisplatin alone in patients with newly diagnosed, advanced biliary tract cancers.

bTACE Plus Lenvatinib and MWA Produces Responses, Tolerability in HCC

January 20th 2023

Blank-microsphere transarterial chemoembolization plus low-dose lenvatinib and sequential microwave ablation elicited responses and a tolerable safety profile in patients with large hepatocellular carcinoma.

Anti-drug Antibodies Do Not Affect Durvalumab Alone, With Tremelimumab in Unresectable HCC

January 20th 2023

The presence of anti-drug antibodies appeared to have no effect on efficacy or safety of durvalumab monotherapy or the STRIDE combination of durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma.

Lenvatinib Following Progression on Immunotherapy Demonstrates Efficacy in Second-line HCC

January 20th 2023

Second-line lenvatinib may produce a survival benefit in patients with advanced hepatocellular carcinoma who have progressed on immunotherapy.

Early Exploration With HER-Vaxx Extends Survival for Patients with HER2+ Gastric/GEJ Adenocarcinoma

January 20th 2023

Patients with HER2-overexpressing metastatic or advanced gastric/gastroesophageal junction adenocarcinoma treated with HER-Vaxx plus standard-of-care chemotherapy had a statistically significant survival benefit compared with those who received chemotherapy alone.

Frontline Zolbetuximab/mFOLFOX6 Prolongs Survival in CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma

January 20th 2023

Frontline zolbetuximab plus mFOLFOX6 significantly improved progression-free and overall survival vs placebo/mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma, according to primary phase 3 data from the SPOTLIGHT trial.

Nivolumab Plus Ipilimumab or Chemo Maintains OS Benefit in ESCC in Long-Term Results

January 20th 2023

Nivolumab in combination with chemotherapy or ipilimumab maintained a clinically meaningful overall survival benefit vs chemotherapy alone in patients with treatment-naïve advanced esophageal squamous cell carcinoma.

Updated CheckMate-649 Data Support Nivolumab/Chemo as Frontline SOC in Advanced Gastric/GEJ/Esophageal Cancer

January 20th 2023

The combination of nivolumab (Opdivo) and chemotherapy continued to provide a clinically meaningful long-term survival benefit and deeper responses than chemotherapy alone in previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, according to 3-year follow-up data from the phase 3 CheckMate-649 trial.

Neoadjuvant Tremelimumab/Durvalumab Elicits Responses in Gastric/GEJ Adenocarcinoma

January 19th 2023

Neoadjuvant treatment with the combination of tremelimumab and durvalumab produced responses and was well tolerated in patients with mismatch repair–deficient and microsatellite instability–high, Epstein-Barr virus–negative gastric or gastroesophageal junction adenocarcinoma.

Adjuvant Atezolizumab/Bevacizumab Combo Meets RFS End Point in Early-Stage HCC

January 19th 2023

Adjuvant treatment with the combination of atezolizumab and bevacizumab demonstrated a statistically significant improvement in recurrence-free survival compared with active surveillance in patients with early-stage hepatocellular carcinoma at high risk of disease recurrence.

IMbrave-150 and HIMALAYA: Clinical Trials of Immune Checkpoint Inhibitor Combinations in HCC

January 19th 2023

The panel reviews the HIMALAYA and IMbrave-150 clinical trials of checkpoint inhibitor combination therapy strategies in advanced HCC.

Combination Therapy with Immune Checkpoint Inhibitors for HCC

January 19th 2023

A deeper dive on immune checkpoint inhibitors in HCC including review of the mechanisms of action of the IO agents.

Dr. Sonbol on Navigating Treatment Selection in Gastroesophageal Cancers

January 16th 2023

Mohamad Bassam Sonbol, MD, discusses key considerations for treatment selection in patients with gastroesophageal junction cancers.